Eli Lilly announced Friday that it is investing an additional $5.3 billion in its manufacturing site in Indiana to boost the ...

Full data from the FLOW study show that Novo Nordisk’s top-selling GLP-1 receptor agonist semaglutide can significantly ...

Johnson & Johnson’s radiopharma candidate JNJ-6420 returned mixed results in an early-stage study, demonstrating strong ...

CEO Pascal Soriot on Tuesday heralded a “new era of growth” for AstraZeneca with plans to launch 20 new medicines in six ...

Phase I/II data for Regeneron Pharmaceuticals’ costimulatory bispecific antibody were disappointing, with only one complete ...

Denmark-based Zealand Pharma announced Thursday the latest Phase I data for its GLP-1/GLP-2 candidate dapiglutide for ...

In advance of Friday’s Endocrinologic and Metabolic Drugs Advisory Committee meeting, the FDA has raised concerns about ...

Nimbus Therapeutics’ small molecule drug candidate NDI-101150 showed strong potential for clinical benefit in patients with ...

An appellate court ruled on Tuesday that pharmaceutical companies can lawfully impose restrictions on covered drugs under the ...

Amid its ongoing efforts to trim $4 billion in spending in 2024, Pfizer in an SEC filing on Wednesday said it is looking to ...

Orna Therapeutics announced Thursday it is acquiring ReNAgade Therapeutics, which launched in May 2023 with $300 million in ...

Riding the growing wave of interest in molecular glue degraders, Takeda has partnered with Chinese biotech Degron ...